Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3480502 | 1.00 | PTGS2 (0.42) | PTGS2AKR1C3AKR1C2AKR1C1ESR2 | |
| SCHEMBL5798485 | 0.96 | PTGS2 (0.45) | PTGS2AKR1C3AKR1C2AKR1C1ESR2 | |
| SCHEMBL3480365 | 0.96 | PTGS2 (0.45) | PTGS2AKR1C3AKR1C2AKR1C1ESR2 | |
| SCHEMBL3480364 | 0.96 | PTGS2 (0.45) | PTGS2AKR1C3AKR1C2AKR1C1ESR2 | |
| SCHEMBL8421848 | 0.95 | PTGS2 (0.44) | PTGS2AKR1C3AKR1C2AKR1C1ESR2 | |
| SCHEMBL8421855 | 0.95 | PTGS2 (0.44) | PTGS2AKR1C3AKR1C2AKR1C1ESR2 | |
| SCHEMBL5794812 | 0.88 | PTGS2 (0.40) | PTGS2ESR2 | |
| SCHEMBL5794805 | 0.88 | PTGS2 (0.40) | PTGS2ESR2 | |
| Bromide SCHEMBL5796091 | 0.87 | PTGS2 (0.39) | PTGS2ESR2 | |
| Bromide SCHEMBL5796086 | 0.87 | PTGS2 (0.39) | PTGS2ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687541-B2 | Prodrugs of diaryl-2-(5H)-furanone cyclooxygenase-2 inhibitors | MERCK & CO., INC. (US) | 2010-03-30 | — | — | US | disclosed |
| EP-1678126-A4 | PRODRUGS OF DIARYL-2-(5H)-FURANONE CYCLOOXYGENASE-2 INHIBITORS | MERCK & CO INC (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20070123587-A1 | Prodrugs of diaryl-2-(5h)-furanone cyclooxygenase-2 inhibitors | MERCK SHARP & DOHME CORP. | 2007-05-31 | — | — | US | disclosed |
| EP-1678126-A2 | PRODRUGS OF DIARYL-2-(5H)-FURANONE CYCLOOXYGENASE-2 INHIBITORS | Merck & Co., Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042476-A2 | PRODRUGS OF DIARYL-2-(5H)-FURANONE CYCLOOXYGENASE-2 INHIBITORS | MERCK & CO., INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123587-A1 | Prodrugs of diaryl-2-(5h)-furanone cyclooxygenase-2 inhibitors | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885AKR1C3 132/4885AKR1C2 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.